X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17060) 17060
Newspaper Article (302) 302
Book Chapter (80) 80
Magazine Article (63) 63
Newsletter (42) 42
Book / eBook (30) 30
Transcript (14) 14
Dissertation (13) 13
Conference Proceeding (12) 12
Book Review (11) 11
Trade Publication Article (6) 6
Publication (5) 5
Reference (4) 4
Streaming Video (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9981) 9981
male (7222) 7222
animals (7121) 7121
serotonin (6403) 6403
pharmacology & pharmacy (5606) 5606
female (4706) 4706
neurosciences (4583) 4583
psychiatry (4039) 4039
rats (3385) 3385
adult (3001) 3001
serotonin antagonists - therapeutic use (2693) 2693
middle aged (2362) 2362
antidepressants (1995) 1995
clinical neurology (1950) 1950
double-blind (1857) 1857
mice (1853) 1853
dose-response relationship, drug (1743) 1743
serotonin - metabolism (1681) 1681
dopamine (1661) 1661
serotonin uptake inhibitors - therapeutic use (1547) 1547
depression (1493) 1493
serotonin antagonists - pharmacology (1493) 1493
aged (1408) 1408
5-ht (1335) 1335
receptors (1301) 1301
brain (1300) 1300
treatment outcome (1300) 1300
rats, sprague-dawley (1291) 1291
antidepressive agents - therapeutic use (1187) 1187
disease models, animal (1184) 1184
double-blind method (1178) 1178
drug therapy (1132) 1132
research (1131) 1131
schizophrenia (1101) 1101
pharmacology (1081) 1081
rodents (1054) 1054
pharmacology/toxicology (1013) 1013
analysis (1008) 1008
receptors, serotonin - drug effects (981) 981
serotonin reuptake inhibitors (971) 971
biomedicine (937) 937
neurology (901) 901
rats, wistar (900) 900
care and treatment (880) 880
anxiety (875) 875
fluoxetine (873) 873
time factors (869) 869
medicine & public health (863) 863
antiemetics - therapeutic use (858) 858
serotonin receptor agonists - pharmacology (840) 840
serotonin uptake inhibitors - pharmacology (840) 840
adolescent (838) 838
serotonin uptake inhibitors (820) 820
antipsychotic agents - therapeutic use (809) 809
drugs (806) 806
receptor (778) 778
brain - metabolism (772) 772
drug therapy, combination (770) 770
health aspects (767) 767
major depression (755) 755
serotonin - pharmacology (755) 755
brain - drug effects (745) 745
behavior, animal - drug effects (741) 741
drug interactions (736) 736
receptors, serotonin - metabolism (734) 734
ondansetron (720) 720
rat (701) 701
biochemistry & molecular biology (700) 700
neurons (685) 685
antidepressive agents - pharmacology (681) 681
depression, mental (681) 681
serotonin - physiology (675) 675
efficacy (672) 672
mental depression (670) 670
serotonin antagonists (662) 662
major depressive disorder (657) 657
vomiting - chemically induced (656) 656
psychopharmacology (641) 641
5-hydroxytryptamine (640) 640
risk factors (635) 635
mental disorders (630) 630
oncology (620) 620
prefrontal cortex (614) 614
clinical trials (611) 611
physiological aspects (610) 610
depressive disorder - drug therapy (608) 608
placebo-controlled trial (602) 602
vomiting - prevention & control (597) 597
pain (596) 596
serotonin receptor agonists - therapeutic use (595) 595
schizophrenia - drug therapy (590) 590
medicine (585) 585
depression - drug therapy (578) 578
piperazines - pharmacology (577) 577
serotonin receptors (577) 577
behavior (572) 572
antidepressant (570) 570
in-vivo (567) 567
in vitro techniques (563) 563
phenols (561) 561
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Robarts - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Gerstein Science - Periodical Stacks (1) 1
OISE - Stacks (1) 1
Online Resources - Online (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Toronto East General Hospital - Chaplain Dept. (1) 1
UTL at Downsview - May be requested (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Northrop Frye (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16938) 16938
German (185) 185
French (140) 140
Japanese (138) 138
Russian (106) 106
Spanish (59) 59
Italian (53) 53
Polish (42) 42
Hungarian (17) 17
Dutch (13) 13
Chinese (11) 11
Portuguese (11) 11
Norwegian (8) 8
Danish (7) 7
Czech (5) 5
Finnish (5) 5
Turkish (5) 5
Serbian (4) 4
Swedish (4) 4
Korean (3) 3
Ukrainian (3) 3
Bulgarian (2) 2
Croatian (2) 2
Hebrew (2) 2
Lithuanian (2) 2
Romanian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Bosnian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | MOUSE | REUPTAKE INHIBITORS | DORSAL RAPHE | PLUS-MAZE BEHAVIOR | NEUROSCIENCES | RECEPTOR ANTAGONIST | HIPPOCAMPUS | 5-HT1A | PHARMACOLOGY & PHARMACY | MICE | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 03/2013, Volume 168, Issue 6, pp. 1388 - 1400
...‐HT3 receptor antagonists are clinically effective in the treatment of nausea and emesis during cancer chemotherapy... 
5‐HT3 receptors | ondansetron | caspase‐8 | TNF‐α | intestinal mucositis | ramosetron | apoptosis | 5‐fluorouracil | caspase‐3 | RECOMMENDED GUIDELINES | caspase-8 | INVOLVEMENT | INDUCTION | TNF | CHEMOTHERAPY | 5-fluorouracil | PATHOGENESIS | INHIBITION | EXPERIMENTAL COLITIS | AVAILABILITY | 5-HT3 receptors | PHARMACOLOGY & PHARMACY | SEROTONIN | EXPRESSION | caspase-3 | Mucositis - metabolism | Intestinal Mucosa - metabolism | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Immunosuppressive Agents - therapeutic use | Gastrointestinal Agents - administration & dosage | Diarrhea - prevention & control | Male | Fluorouracil - antagonists & inhibitors | Mucositis - prevention & control | Intestinal Mucosa - drug effects | Serotonin 5-HT3 Receptor Antagonists - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Mucositis - pathology | Drug Interactions | Benzimidazoles - administration & dosage | Fluorouracil - adverse effects | Intestinal Mucosa - immunology | Apoptosis Regulatory Proteins - genetics | Benzimidazoles - adverse effects | Cytokines - genetics | Benzimidazoles - therapeutic use | Cytokines - metabolism | Mice, Inbred C57BL | Immunosuppressive Agents - antagonists & inhibitors | Mucositis - chemically induced | Apoptosis Regulatory Proteins - metabolism | Gene Expression Regulation - drug effects | Serotonin 5-HT3 Receptor Antagonists - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Animals | Ondansetron - therapeutic use | Serotonin 5-HT3 Receptor Antagonists - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Apoptosis Regulatory Proteins - antagonists & inhibitors | Gastrointestinal Agents - therapeutic use | Diarrhea - etiology | Immunosuppressive Agents - adverse effects | Mice | Ondansetron - adverse effects | Serotonin 5-HT3 Receptor Agonists - therapeutic use | Intestinal Mucosa - pathology | Serotonin 5-HT3 Receptor Agonists - adverse effects | Chemotherapy | Nausea | Cancer | Fluorouracil | Apoptosis | Research Papers | TNF-α
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 11/2012, Volume 68, Issue 11, pp. 1465 - 1472
Buspirone, a partial 5HT1A agonist and D2 and D3 antagonist, has shown promising antiemetic efficacy when given parenterally in animal models, but its efficacy for the prevention of postoperative nausea and vomiting (PONV... 
Biomedicine | Buspirone | Pharmacology/Toxicology | Randomised clinical trial | Antiemetic | Postoperative nausea and vomiting | CATS | MANAGEMENT | 5-HT1A RECEPTORS | ONDANSETRON | AGONISTS | FLESINOXAN | PROPHYLAXIS | ANXIOLYTICS | PHARMACOLOGY & PHARMACY | 5-HT(1A) RECEPTOR | CISPLATIN-INDUCED EMESIS | Anti-Anxiety Agents - administration & dosage | Injections, Intravenous | Buspirone - blood | Dopamine Antagonists - pharmacokinetics | Humans | Middle Aged | Receptors, Dopamine D3 - metabolism | Antiemetics - administration & dosage | Male | Buspirone - pharmacokinetics | Receptors, Dopamine D2 - metabolism | Dopamine Antagonists - administration & dosage | Incidence | Dose-Response Relationship, Drug | Young Adult | Anti-Anxiety Agents - pharmacokinetics | Buspirone - administration & dosage | Antiemetics - pharmacokinetics | Antiemetics - therapeutic use | Aged, 80 and over | Adult | Anti-Anxiety Agents - adverse effects | Antiemetics - adverse effects | Female | Anti-Anxiety Agents - therapeutic use | Buspirone - adverse effects | Receptors, Dopamine D3 - antagonists & inhibitors | Buspirone - therapeutic use | Receptor, Serotonin, 5-HT1A - metabolism | Postoperative Nausea and Vomiting - epidemiology | Double-Blind Method | Dopamine Antagonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Postoperative Nausea and Vomiting - prevention & control | Receptor, Serotonin, 5-HT1A - chemistry | Buspirone - analogs & derivatives | Dopamine Antagonists - adverse effects | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Aged | Dopamine D2 Receptor Antagonists | Postoperative Nausea and Vomiting - blood | Prevention | Complications and side effects | Buspirone hydrochloride | Adults | Nausea | Analysis | Postoperative period | Vomiting | Clinical trials | Pharmacology | Drug therapy | Clinical outcomes
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 02/2015, Volume 172, Issue 4, pp. 1136 - 1147
Journal Article
Neuroscience, ISSN 0306-4522, 2012, Volume 215, pp. 196 - 208
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2018, Volume 319, Issue 2, pp. 130 - 142
IMPORTANCE: New therapeutic approaches for Alzheimer disease (AD) are needed. OBJECTIVE: To assess whether idalopirdine, a selective 5-hydroxytryptamine-6 receptor antagonist, is effective for symptomatic treatment of mild to moderate AD... 
DONEPEZIL | 5-HT6 RECEPTOR ANTAGONIST | MODERATE | MEDICINE, GENERAL & INTERNAL | DOUBLE-BLIND | SEROTONIN | SB-742457 | RATING-SCALE | VALIDITY | Serotonin Antagonists - administration & dosage | Benzylamines - adverse effects | Humans | Middle Aged | Male | Indans - therapeutic use | Benzylamines - administration & dosage | Indoles - administration & dosage | Dose-Response Relationship, Drug | Serotonin Antagonists - adverse effects | Treatment Failure | Aged, 80 and over | Female | Drug Therapy, Combination | Accidental Falls | Alzheimer Disease - psychology | Double-Blind Method | Alzheimer Disease - drug therapy | Serotonin Antagonists - therapeutic use | Cognition - drug effects | Indoles - adverse effects | Galantamine - therapeutic use | Piperidines - therapeutic use | Cholinesterase Inhibitors - adverse effects | Indoles - therapeutic use | Aged | Rivastigmine - therapeutic use | Cholinesterase Inhibitors - therapeutic use | Benzylamines - therapeutic use | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Clinical trials | Dosage and administration | Cholinesterase inhibitors | Alzheimer's disease | Drugs | Medical research | Activities of daily living | Galantamine | Neurodegenerative diseases | Serotonin | Medical treatment | Cognitive ability | Cognition | Patients | Cholinesterase | Randomization | Safety engineering | Donepezil | Alzheimers disease | Original Investigation | Research
Journal Article
2003, Volume 63, Issue 16, 41
... Antagonists ...... 
Methysergide, therapeutic use | Headache, treatment | Antiepileptic drugs, therapeutic use | Capsaicin, therapeutic use | Antimigraines, therapeutic use | Research and development | Cluster headache, treatment | Oxygen inhalation therapy | Leuprorelin, therapeutic use | Somatostatin, therapeutic use | Local anaesthetics, therapeutic use | Surgery | Civamide, therapeutic use | Clonidine, therapeutic use | Dihydroergotamine mesylate, therapeutic use | Nimodipine, therapeutic use | Lidocaine, therapeutic use | Calcium channel antagonists, therapeutic use | Methylergometrine, therapeutic use | Olanzapine, therapeutic use | Nerve block | Zolmitriptan, therapeutic use | Dehydroemetine, therapeutic use | Valproic acid, therapeutic use | Migraine, treatment | Baclofen, therapeutic use | Melatonin, therapeutic use | Lithium, therapeutic use | Verapamil, therapeutic use | Ergotamine, therapeutic use | Chlorpromazine, therapeutic use | Serotonin 1D receptor agonists, therapeutic use | Sumatriptan, therapeutic use | Cocaine, therapeutic use | Analgesics, therapeutic use | Pizotifen, therapeutic use | Corticosteroids, therapeutic use | Gabapentin, therapeutic use | Topiramate, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | SUNCT SYNDROME | CONJUNCTIVAL INJECTION | PROPHYLACTIC TREATMENT | PHARMACOLOGY & PHARMACY | TOXICOLOGY | UNILATERAL NEURALGIFORM HEADACHE | PLACEBO-CONTROLLED TRIAL | LITHIUM-CARBONATE | BRAIN-STEM ACTIVATION | MIGRAINOUS NEURALGIA | CHRONIC PAROXYSMAL HEMICRANIA | EPISODIC CLUSTER HEADACHE | Analgesics - pharmacology | Analgesics - therapeutic use | Ergot Alkaloids - pharmacology | Oxygen - pharmacology | Drug Administration Schedule | Humans | Sumatriptan - therapeutic use | Trigeminal Neuralgia - diagnosis | Trigeminal Neuralgia - physiopathology | Vascular Headaches - diagnosis | Male | Anesthetics, Local - pharmacology | Oxazolidinones - therapeutic use | Vascular Headaches - physiopathology | Sumatriptan - pharmacology | Oxazolidinones - pharmacology | Trigeminal Neuralgia - drug therapy | Ergot Alkaloids - therapeutic use | Female | Anesthetics, Local - therapeutic use | Tryptamines | Vascular Headaches - drug therapy
Book Review
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9656, pp. 2115 - 2123
Journal Article